Investor Engagement Perrigo is actively engaging investors and participates in major conferences, signaling readiness to discuss strategy and financial health. This presents an opening for sales outreach around cost efficiency, product value, and potential partnerships that align with investor narratives.

Board Expansion Recent additions to the Perrigo board with expertise in consumer products, retail, and digital transformation suggest a strategic emphasis on omnichannel growth and modernization. Target opportunities in digital marketing services, analytics, and enhanced distribution capabilities.

Financial Performance Q2 2026 revenue of about $1.02B with a slight year-over-year decline but strong earnings beat indicates a focus on efficiency and portfolio optimization. Explore value-led procurement, cost-saving technologies, and scalable OTC/generic product support solutions.

Leadership Change Executive transition with interim CEO and ongoing leadership adjustments may create urgency for external partnerships to stabilize operations, supply chain improvements, and strategic initiatives—all potential entry points for consulting, ERP, and API-enabled solutions.

Product Focus Perrigo’s portfolio spans OTC, generic Rx, infant formulas, nutrition, dietary supplements, and APIs. This breadth offers cross-sell potential for manufacturing optimization, quality compliance tooling, and integrated analytics across multiple product lines and regulatory regimes.